Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

This study is for children aged two years or younger who have been diagnosed with a specific type of brain tumour called ependymoma. It's important that their tumour is a particular grade (WHO grade 2 or 3) and not other specific types of ependymoma.

To join, children must have either had their tumour completely removed by surgery, or have some tumour remaining, or have the cancer spread. They should have had surgery or previous treatment for their tumour within the last three weeks, or be unable to have chemotherapy for personal reasons or doctor's advice.

Children must also be generally well enough to receive fluids through a drip and not have any active infections. This study is not looking for children who have certain other types of ependymoma or who don't meet these specific health conditions.

If your child takes part in this study, they will receive a standard combination of chemotherapy medicines. These medicines, including vincristine, carboplatin, methotrexate, cyclophosphamide, and cisplatin, will be given through a drip (IV) on specific days over an eight-week cycle. This treatment will repeat for seven cycles, as long as the disease doesn't get worse and your child tolerates the treatment well. The doctors might adjust part of the methotrexate dose for some children.

Throughout the study, your child will have regular check-ups. These include physical and nervous system examinations, as well as special scans like MRI to look at the brain. There will also be tests to assess their hearing, kidney function, and thinking abilities over time. The study will continue to monitor these aspects after the main treatment is finished, to understand any long-term effects. This is a multi-centre study, meaning it happens at different hospitals.